Loss of BCL-W does not sensitize BL or DLBCL cell lines to BH3-mimetic drugs. Viability of BCL-W–disrupted (sgBCL-W) and control (sgNT) cells following treatment with indicated dose of BH3-mimetic drugs for 24 hours: S63845 (MCL-1 inhibitor), ABT-199 (BCL-2 inhibitor), ABT-737 (BCL-2/BCL-XL/BCL-W inhibitor), and A-1331852 (BCL-XL inhibitor). Cell viability was measured by the proportion of cells that were Annexin V and DAPI double-negative by flow cytometry, and results were normalized to a DMSO-treated control sample. Loss of BCL-W did not sensitize any cell lines to any of the BH3-mimetic drugs tested (Student t test, P > .05 for all). Error bars represent the SD for 3 independent experiments. Significance is indicated (Student t test, *P < .05).